AstraZeneca PLC (FRA:ZEG)
139.50
-1.30 (-0.92%)
At close: Sep 5, 2025
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B USD in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.49
Revenue / Employee
$599.16K
Employees
94,300
Market Cap
215.99B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Rheinmetall AG | 10.67B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Siemens Energy AG | 38.39B |
Deutsche Bank Aktiengesellschaft | 30.07B |
AstraZeneca News
- 19 hours ago - TN signs MoUs with Hinduja, AstraZeneca - The Times of India
- 3 days ago - Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Benzinga
- 3 days ago - AstraZeneca, Corning And More On CNBC's 'Final Trades' - Benzinga
- 3 days ago - Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing - Wallstreet:Online
- 3 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 3 days ago - Final Trades: AstraZeneca, Corning, the IBIT and the SPHD - CNBC
- 4 days ago - Mineralys (MLYS) Soars 85% After AstraZeneca's Drug Trial Success - GuruFocus
- 4 days ago - Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug - Seeking Alpha